News & Events CTI Clinical Trial and Consulting Services Announces that John R. Edwards, MD has joined as Medical Director

CTI Clinical Trial and Consulting Services Announces that John R. Edwards, MD has joined as Medical Director

September 16, 2011

CTI Clinical Trial and Consulting Services (CTI) announces the addition of John R. Edwards, MD as Medical Director. Dr. Edwards brings to CTI extensive clinical experience in hematology, oncology and stem cell therapy.

Dr. Edwards comes to CTI from Lifeforce Cryobanks where he served as the President/COO/CMO of the organization, and is a pioneer in the collection, processing and banking of umbilical cord blood stem cells. In addition, Dr. Edwards was also the Founding Medical Director of the Florida Hospital Cancer Institute Bone Marrow Transplant Program, where he established the adult and pediatric blood and marrow transplant program as well as an active research program. Previously, he was an Assistant Professor in pediatric hematology/oncology at Vanderbilt University and had been an instructor at the University of Florida and University of California, San Francisco.

Dr. Edwards is a member of the International Society for Cellular Therapy (ISCT) and The American Society for Blood and Marrow Transplant (ASBMT). He earned his Bachelor of Arts and Doctor of Medicine from the University of Florida. Dr. Edwards performed his Residency in Pediatrics and Fellowships in Pediatric Immunology and Pediatric Hematology/Oncology at the University of California, San Francisco. He also performed additional Fellowship training at the University of Florida and is board certified in Pediatric Hematology/Oncology.

“Over the last three years, CTI has been very active in the development of innovative oncology and stem cell programs. John brings a wealth of clinical and industry expertise in hematology, oncology and stem cell transplantation to CTI,” states Lynn Fallon, Executive Vice President and President, Consulting Services at CTI. “We are pleased to have him join our Medical Affairs Team to enable us to expand our licensing and acquisition, drug development, and clinical trial services to current and future clients.”

Subscribe to our mailing list

* indicates required